One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Nivolumab for Patients With High-Risk Oral Leukoplakia
Glenn J. Hanna, MD1; Alessandro Villa, DDS, PhD2; Shuvro P. Nandi, PhD3,4; Ruichao Shi5; Anne ONeill5; Mofei Liu5; Charles T. Quinn1; Nathaniel S. Treister, DMD6; Herve Y. Sroussi, DMD, PhD6; Piamkamon Vacharotayangul, DDS, PhD6; Laura A. Goguen, MD7; Donald J. Annino Jr, MD, DMD7; Eleni M. Rettig, MD7; Vickie Y. Jo, MD8; Kristine S. Wong, MD8; Patrick Lizotte, PhD1,9; Cloud P. Paweletz, PhD1,9; Ravindra Uppaluri, MD, PhD7; Robert I. Haddad, MD1; Ezra E. W. Cohen, MD3; Ludmil B. Alexandrov, PhD3,4,10; William N. William Jr, MD11; Scott M. Lippman, MD3; Sook-bin Woo, DMD6
doi : 10.1001/jamaoncol.2023.4853
January 2024, Vol 10, No. 1, Pages 25-148
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
Yusuke Okuma, MD, PhD1; Kaoru Kubota, MD, PhD2; Mototsugu Shimokawa, PhD3; Kana Hashimoto, MD4; Yosuke Kawashima, MD5; Tomohiro Sakamoto, MD, PhD6; Hiroshi Wakui, MD, PhD7; Shuji Murakami, MD, PhD8; Kyoichi Okishio, MD, PhD9; Kenji Hayashihara, MD, PhD10; Yuichiro Ohe, MD, PhD1; and the Tokyo Cooperative Oncology Group (TCOG)
Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer
Jesper Nors, MD1,2; Lene Hjerrild Iversen, MD, DMSc2,3; Rune Erichsen, MD, PhD2,4,5; Kåre Andersson Gotschalck, MD, PhD2,6; Claus Lindbjerg Andersen, PhD1,2
Breast Cancer Incidence After a False-Positive Mammography Result
Xinhe Mao, MSc1; Wei He, PhD1,2,3; Keith Humphreys, PhD1; Mikael Eriksson, PhD1; Natalie Holowko, PhD1,4; Haomin Yang, PhD1,5; José Tapia, MSc1; Per Hall, PhD1,6; Kamila Czene, PhD1
Global Stage Distribution of Breast Cancer at Diagnosis
Javier David Benitez Fuentes, MD1,2,3; Eileen Morgan, PhD1; Alicia de Luna Aguilar, MD2,3; Allini Mafra, PhD1; Richa Shah, PhD1; Francesco Giusti, PhD1,7; Jérôme Vignat, MSc1; Ariana Znaor, MD1; Carina Musetti, MD4; Cheng-Har Yip, MD5,6; Liesbet Van Eycken, MD1,7; Elima Jedy-Agba, PhD8; Marion Piñeros, MD1; Isabelle Soerjomataram, PhD1
Practice Patterns for Organ Preservation in US Patients With Rectal Cancer, 2006-2020
Anthony Loria, MD, MSCI1; Mohamedtaki A. Tejani, MD2; Larissa K. Temple, MD, MSc1; Carla F. Justiniano, MD, MPH3; Alexa D. Melucci, MD, MS1; Adan Z. Becerra, PhD4; John R. T. Monson, MD5; Christopher T. Aquina, MD5; Fergal J. Fleming, MD, MPH1
Cost Savings and Waste Reduction Through Redispensing Unused Oral Anticancer Drugs
Elisabeth M. Smale, PharmD1; Bart J. F. van den Bemt, PharmD, PhD1,2; Eibert R. Heerdink, MS, PhD3,4,5; Ingrid M. E. Desar, MD, PhD6; Toine C. G. Egberts, PharmD, PhD3,4; Charlotte L. Bekker, MS, PhD1; for the ROAD Study Group
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence
Kuniko Sunami, MD, PhD1; Yoichi Naito, MD2; Yusuke Saigusa, PhD3; Toraji Amano, MD, PhD4; Daisuke Ennishi, MD, PhD5; Mitsuho Imai, MD, PhD6,7; Hidenori Kage, MD, PhD8; Masashi Kanai, MD, PhD9; Hirotsugu Kenmotsu, MD, PhD10; Keigo Komine, MD, PhD11; Takafumi Koyama, MD, PhD12; Takahiro Maeda, MD, PhD13; Sachi Morita, MD, PhD14; Daisuke Sakai, MD15; Makoto Hirata, MD, PhD16; Mamoru Ito, MD, PhD17; Toshiyuki Kozuki, MD, PhD18; Hiroyuki Sakashita, MD, PhD19; Hidehito Horinouchi, MD, PhD20; Yusuke Okuma, MD, PhD20; Atsuo Takashima, MD, PhD21; Toshio Kubo, MD, PhD22; Shuichi Hironaka, MD, PhD23; Yoshihiko Segawa, MD, PhD24; Yoshihiro Yakushijin, MD, PhD25; Hideaki Bando, MD, PhD6; Akitaka Makiyama, MD, PhD26; Tatsuya Suzuki, MD, PhD27; Ichiro Kinoshita, MD, PhD4; Shinji Kohsaka, MD, PhD28; Yuichiro Ohe, MD, PhD20; Chikashi Ishioka, MD, PhD11; Kouji Yamamoto, PhD3; Katsuya Tsuchihara, MD, PhD29; Takayuki Yoshino, MD, PhD30
Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer
Lauren McVicker, PhD1; Alexander M. Labeit, PhD1; Carol A. C. Coupland, PhD2,3; Blánaid Hicks, PhD1; Carmel Hughes, PhD4; Úna McMenamin, PhD1; Stuart A. McIntosh, PhD5,6; Peter Murchie, MD7; Chris R. Cardwell, PhD1
Assessment of Changes in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US
Leticia M. Nogueira, PhD, MPH1; Elizabeth J. Schafer, MPH1; Qinjin Fan, PhD1; Nikita Sandeep Wagle, MBBS, MHA, PhD1; Jingxuan Zhao, MPH1; Kewei Sylvia Shi, MPH1; Xuesong Han, PhD1; Ahmedin Jemal, DVM, PhD1; K. Robin Yabroff, PhD1
Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment
Daan W. Huntjens, PharmD1,2; Joost W. Vanhommerig, PhD3; Willem van de Veen, PhD4; Mirjam Crul, PhD1
Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell Tumors
Jennifer King, MD1; Ryan Ashkar, MD1; Kenneth Kesler, MD2; Sandra K. Althouse, MS3; Nasser H. Hanna, MD1; Lawrence H. Einhorn, MD1; Nabil Adra, MD1
Distribution of Cancer Care Resources Across US Hospitals by Patient Race and Ethnicity
Gracie Himmelstein, MD, PhD1; Patricia A. Ganz, MD1,2
Mortality and Hospitalization Risks in Patients With Cancer and the SARS-CoV-2 Omicron Variant
Jonathan Ofer, MD1; Genady Drozdinsky, MD2; Bar Basharim, MD2; Adi Turjeman, PhD2,3; Noa Eliakim-Raz, MD2,3; Salomon M. Stemmer, MD1,3
Contemporary Trends in Reviewing Test Results Through the Electronic Patient Portal Among Patients With Cancer
Sheena Bhalla, MD1,2; Tanushree Prasad, MA3; Donglu Xie, MS4; David E. Gerber, MD1,2,3
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy
Marco Ventin, MD1; Giulia Cattaneo, PhD1; Luke Maggs, PhD1; Shahrzad Arya, MD1; Xinhui Wang, MD, PhD1; Cristina R. Ferrone, MD2
Structural Racism and Lung Cancer Risk
Sidra N. Bonner, MD, MPH, MSc1,2; Richard Curley, DrPH3; Kyra Love, MMLIS4; Tola Akande, BA3; Aamna Akhtar, BA3; Loretta Erhunmwunsee, MD3,5
A Young Man With a Neck Mass and Hypereosinophilia
Maha Hameed, MBBS1; Nasir Bakshi, MBBS, MD2; Mansour Alfayez, MD, MS3
Derailing Carcinogens—Oncologists and the Ohio Train Derailment
Leticia M. Nogueira, PhD, MPH1; Jodi D. Sherman, MD2,3; James M. Shultz, PhD, MS4
Expanding Access to High-Quality Cancer Care Through Policy—California Cancer Care Equity Act
Adrian Diaz, MD, MPH1; Andrew Loehrer, MD, MPH2; Timothy M. Pawlik, MD, PhD, MPH, MBA1
Moving Toward Personalized Colorectal Cancer Follow-Up Care
Dong Hang, PhD1; Markus Dines Knudsen, PhD2,3; Mingyang Song, MD, ScD2,4,5
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?
Bishal Gyawali, MD, PhD1,2,3; Garth W. Strohbehn, MD, MPhil4,5
Osimertinib in Patients With Non–Small Cell Lung Cancer and Uncommon EGFR Mutations—Chasing Unicorns?
Victoria E. Wang, MD, PhD1,2; Justin F. Gainor, MD3
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer
Dipesh Uprety, MD1; Howard (Jack) West, MD2
Racial Disparities and Survival Outcomes in Breast Cancer
Haruki Shigeta1,2; Akihiko Ozaki, MD, DrPH1,3; Tetsuya Tanimoto, MD1,4
Racial Disparities and Survival Outcomes in Breast Cancer—Reply
Kent F. Hoskins, MD1,2; Garth H. Rauscher, PhD2,3
Bacterial Decolonization for Prevention of Radiation Dermatitis—Fragility Index Analysis
Shubhangi Shah, BMSc1; Ronald Chow, MS2; Charles B. Simone II, MD2
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck
Layla Parast, PhD1; Lu Tian, ScD2; Lee-Jen Wei, PhD3
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck
Oliver Klein, MD1
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck—Reply
Kevin J. Harrington, MBBS, PhD1; Robert Haddad, MD2
